Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck M-M-R II by Quarter
M-M-R II (measles, mumps and rubella virus vaccine) — Worldwide sales ($M) ($M)
Merck M-M-R II: $96M in Q2 2026, up 1.1% from a year earlier.
Latest, Q2 2026
96
Period ended Jun 30, 2026
Change on a year earlier
+1.1%
95 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below
Where the Q2 2026 figure comes from
“|| M-M-R II | 96 | 95 | 1 | % | 1 | % | 201 | 264 | (24) | % | (25) | %”
Source: Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K MD&A Pediatric Vaccines Disclosure (Q4 derived as Full Year − 9M).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up M-M-R II
Cite this data
StockData. (2026). Merck M-M-R II ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-mmr-ii
See every metric in the Merck KPI table. Data updated Oct 26, 2026.